AngioDynamics designs, manufactures, and sells various medical, surgical, and diagnostic devices for vascular access, surgery, peripheral vascular disease, and oncology in the United States and internationally. The company was founded in 1988 and is based in Latham, New York.
ANGO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Angiodynamics Inc. To summarize, we found that Angiodynamics Inc ranked in the 0th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 100%. In terms of the factors that were most noteworthy in this DCF analysis for ANGO, they are:
The company's compound free cash flow growth rate over the past 5.65 years comes in at -0.74%; that's greater than only 0.58% of US stocks we're applying DCF forecasting to.
The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than only 10.81% of the free cash flow producing stocks we're observing.
The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ANGO, try AGHC, ALC, CSII, ELAN, and HAPP.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the UBS Virtual Global Healthcare Conference at 9:10 a.m. ET on Monday, May 18, 2020. A live webcast